The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 23, 2017

Filed:

Jul. 22, 2015
Applicant:

Pulse Biosciences, Inc., Burlingame, CA (US);

Inventors:

Richard Lee Nuccitelli, Millbrae, CA (US);

Pamela Nuccitelli, Millbrae, CA (US);

Joanne Lum, San Francisco, CA (US);

Kaying Lui, Millbrae, CA (US);

Brian Athos, San Francisco, CA (US);

Mark Kreis, San Francisco, CA (US);

Zachary Mallon, San Francisco, CA (US);

Jon Berridge, Oakland, CA (US);

Assignee:

PULSE BIOSCIENCES, INC., Burlingame, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61N 1/00 (2006.01); A61N 1/30 (2006.01); A61N 1/36 (2006.01); A61N 1/05 (2006.01); C12N 15/87 (2006.01); A61B 18/14 (2006.01); A61B 18/00 (2006.01); A61N 1/40 (2006.01); C12N 13/00 (2006.01); C12M 1/42 (2006.01); A61N 1/04 (2006.01); A61N 1/32 (2006.01); A61N 1/372 (2006.01);
U.S. Cl.
CPC ...
A61N 1/36 (2013.01); A61N 1/05 (2013.01); A61N 1/32 (2013.01); A61B 18/1477 (2013.01); A61B 2018/0016 (2013.01); A61B 2018/00613 (2013.01); A61N 1/0412 (2013.01); A61N 1/0424 (2013.01); A61N 1/327 (2013.01); A61N 1/37229 (2013.01); A61N 1/40 (2013.01); C12M 35/02 (2013.01); C12N 13/00 (2013.01); C12N 15/87 (2013.01);
Abstract

Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on size and type of a tumor to stimulate an immune response against the tumor and other tumors in a subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.


Find Patent Forward Citations

Loading…